文献速递浆细胞疾病

维奈克拉耐药导致多发性骨髓瘤对标准抗骨髓瘤药物广泛耐药,但对免疫治疗仍敏感

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
PubMed 文献 · Blood Adv · 2024-01-01

研究在携带t(11:14)的敏感多发性骨髓瘤细胞模型中建立维奈克拉耐药单细胞克隆,发现获得性耐药表现为线粒体始动减少和BCL-2家族蛋白表达改变,导致对标准抗骨髓瘤药物广泛耐药,但耐药细胞仍对免疫治疗敏感。

要点

  • 维奈克拉耐药的多发性骨髓瘤细胞线粒体始动减少且BCL-2家族蛋白表达改变。
  • 维奈克拉耐药细胞对标准抗骨髓瘤药物广泛耐药。
  • 维奈克拉耐药细胞仍对免疫治疗敏感,提示需考虑维奈克拉方案后治疗的序贯安排。

核心结论

  • 获得性维奈克拉耐药以线粒体始动减少和BCL-2家族蛋白表达改变为特征,导致对标准抗骨髓瘤药物广泛耐药,但耐药细胞仍对免疫治疗敏感。

研究设计与样本

  • 在敏感的t(11:14)多发性骨髓瘤细胞模型中生成单细胞维奈克拉耐药细胞系,研究耐药机制及对其他治疗的敏感性。

主要发现

  • 维奈克拉耐药细胞线粒体始动减少,BCL-2家族蛋白表达发生改变。
  • 维奈克拉耐药细胞对标准抗骨髓瘤药物出现广泛耐药。
  • 维奈克拉耐药细胞仍对免疫治疗敏感。

临床怎么用

  • 作者认为需考虑维奈克拉方案后免疫治疗的适当序贯安排。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To our knowledge, venetoclax is the first example of personalized medicine for multiple myeloma (MM), with meaningful clinical activity as a monotherapy and in combination in patients with myeloma harboring the t(11:14) translocation. However, despite the high response rates and prolonged progression-free survival, a significant proportion of patients eventually relapse. Here, we aim to study adaptive molecular responses after the acquisition of venetoclax resistance in sensitive t(11:14) MM cell models. We therefore generated single-cell venetoclax-resistant t(11:14) MM cell lines and investigated the mechanisms contributing to resistance as well as the cells' sensitivity to other treatments. Our data suggest that acquired resistance to venetoclax is characterized by reduced mitochondrial priming and changes in B-cell lymphoma-2 (BCL-2) family proteins' expression in MM cells, conferring broad resistance to standard-of-care antimyeloma drugs. However, our results show that the resistant cells are still sensitive to immunotherapeutic treatments, highlighting the need to consider appropriate sequencing of these treatments after venetoclax-based regimens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Deng S, Derebail S, Weiler VJ, et al. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies. Blood Adv. 2024. PMID: 38861273. doi:10.1182/bloodadvances.2023012298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。